Morgan Stanley Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) and lowered the price target from $47 to $31.
September 18, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics' price target has been lowered from $47 to $31 by Morgan Stanley, while maintaining an Equal-Weight rating.
The lowering of the price target by a significant margin indicates a less optimistic outlook for the company's stock in the short term. This could potentially lead to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100